R S Keefe

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
  2. ncbi request reprint Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia
    R S Keefe
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    Arch Gen Psychiatry 54:169-76. 1997
  3. ncbi request reprint Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
    P D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 158:176-84. 2001
  4. ncbi request reprint Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
    M Davidson
    Department of Psychiatry, Mount Sinai School of Medicine, New York
    Am J Psychiatry 152:197-207. 1995
  5. ncbi request reprint Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 33:1217-28. 2008
  6. ncbi request reprint Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
  7. pmc How should DSM-V criteria for schizophrenia include cognitive impairment?
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Schizophr Bull 33:912-20. 2007
  8. ncbi request reprint Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
  9. ncbi request reprint AKT1 and neurocognition in schizophrenia
    Andrea Poyastro Pinheiro
    Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA
    Aust N Z J Psychiatry 41:169-77. 2007
  10. ncbi request reprint Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients
    Marie Cecile Bralet
    Department of Psychiatry Fitz James 5, Clermont de l Oise, Mental Health Hospital, 2 rue des Finets, 60600 Clermont de l Oise, France
    Eur Psychiatry 22:365-70. 2007

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
    ....
  2. ncbi request reprint Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia
    R S Keefe
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    Arch Gen Psychiatry 54:169-76. 1997
    ..We investigated whether these hypothesized components of a schizophrenia-related phenotype are associated with one another or are independent in nonpsychotic relatives of patients with schizophrenia...
  3. ncbi request reprint Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
    P D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 158:176-84. 2001
    ..The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice...
  4. ncbi request reprint Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
    M Davidson
    Department of Psychiatry, Mount Sinai School of Medicine, New York
    Am J Psychiatry 152:197-207. 1995
    ....
  5. ncbi request reprint Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 33:1217-28. 2008
    ..A significant and surprisingly large placebo/practice effect was observed among placebo-treated patients, and is a serious consideration in future clinical trial study designs for potential cognitive enhancing compounds in schizophrenia...
  6. ncbi request reprint Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  7. pmc How should DSM-V criteria for schizophrenia include cognitive impairment?
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Schizophr Bull 33:912-20. 2007
    ..Given the current emphasis on the development of cognitive treatments, the evaluation of cognition in schizophrenia is an essential component of mental health education...
  8. ncbi request reprint Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  9. ncbi request reprint AKT1 and neurocognition in schizophrenia
    Andrea Poyastro Pinheiro
    Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA
    Aust N Z J Psychiatry 41:169-77. 2007
    ..Therefore, the association of genetic variation in AKT1 with neurocognition was investigated in patients with schizophrenia...
  10. ncbi request reprint Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients
    Marie Cecile Bralet
    Department of Psychiatry Fitz James 5, Clermont de l Oise, Mental Health Hospital, 2 rue des Finets, 60600 Clermont de l Oise, France
    Eur Psychiatry 22:365-70. 2007
    ....
  11. ncbi request reprint Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  12. ncbi request reprint Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  13. ncbi request reprint Risperidone and cognitive function in children with disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Biol Psychiatry 62:226-34. 2007
    ..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed...
  14. ncbi request reprint Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
    Robert A Rosenheck
    University of North Carolina, Chapel Hill, USA
    Am J Psychiatry 163:2080-9. 2006
    ..Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted...
  15. ncbi request reprint Cognition as an outcome measure in schizophrenia
    Michael S Kraus
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Br J Psychiatry Suppl 50:s46-51. 2007
    ..Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning...
  16. doi request reprint Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study
    Michael F Green
    Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm 2263, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:221-8. 2008
    ..e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity...
  17. pmc Implementation considerations for multisite clinical trials with cognitive neuroscience tasks
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Schizophr Bull 34:656-63. 2008
    ..Suggestions for overcoming these implementation challenges are offered...
  18. doi request reprint Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
    Richard S E Keefe
    Department of Psychiatry, Box 3207, Duke University Medical Center, Durham, North Carolina 27710, USA
    Schizophr Res 102:108-15. 2008
    ..An education-correction factor was calculated and recommended only for non-schizophrenia patients. Eight different verbal memory tests were found to have equivalent levels of difficulty...
  19. doi request reprint What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  20. doi request reprint Relationship of cognition and psychopathology to functional impairment in schizophrenia
    Somaia Mohamed
    New England Mental Illness, Research, Education and Clinical Center, Department of Veterans Affairs, West Haven, Conn 06516, USA
    Am J Psychiatry 165:978-87. 2008
    ..This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)...
  21. doi request reprint The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition
    James J Crowley
    Department of Genetics, University of North Carolina at Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1298-300. 2008
    ..We were unable to replicate previous associations of rs6994992 with schizophrenia and, moreover, did not find significant associations with age of onset, an estimate of pre-morbid IQ, or neurocognition...
  22. ncbi request reprint Cognitive deficits in patients with schizophrenia: effects and treatment
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    J Clin Psychiatry 68:8-13. 2007
    ..Therefore, cognitive deficits should be included in the diagnostic criteria for schizophrenia. Clinicians need to focus treatment options on helping patients to regain premorbid levels of cognitive functioning...
  23. pmc Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia
    S Kristian Hill
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Int Neuropsychol Soc 14:209-21. 2008
    ....
  24. doi request reprint Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
    Sandra G Resnick
    New England Mental Illness Research Education and Clinical Center, Yale University School of Medicine, VA Connecticut Health Care System, NEPEC 182, 950 Campbell Ave, West Haven, CT 06516, USA
    J Behav Health Serv Res 35:215-25. 2008
    ..Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine...
  25. doi request reprint The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
    Keith H Nuechterlein
    Department of Psychology, UCLA Semel Institute for Neuroscience and Human Behavior, 300 Medical Plaza, Rm 2251, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:203-13. 2008
    ....
  26. doi request reprint The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
    Robert S Kern
    Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA
    Am J Psychiatry 165:214-20. 2008
    ..S. community sample with the battery administered as a unit...
  27. ncbi request reprint A longitudinal study of neurocognitive function in individuals at-risk for psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Schizophr Res 88:26-35. 2006
    ..The time course and predictive value of cognitive deficits in the development of psychosis has not been established...
  28. ncbi request reprint Sensory acuity and reasoning in delusional disorder
    Charles R Conway
    Duke University Department of Psychiatry, John Umstead Hospital, Butner, NC 27509, USA
    Compr Psychiatry 43:175-8. 2002
    ..Further, the study suggests that this reasoning difference generalizes to events outside the DD subjects' delusional realm and can be evoked in an experimental environment...
  29. ncbi request reprint Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    Biol Psychiatry 59:97-105. 2006
    ..Neurocognitive deficits are severe in first-episode psychosis...
  30. ncbi request reprint A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 31:5-19. 2005
    ....
  31. ncbi request reprint Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  32. ncbi request reprint Defining a cognitive function decrement in schizophrenia
    Richard S E Keefe
    Duke University, School of Medicine, Durham, North Carolina, USA
    Biol Psychiatry 57:688-91. 2005
    ....
  33. ncbi request reprint Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    Michael F Green
    Neuropsychiatric Institute, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Biol Psychiatry 56:301-7. 2004
    ..The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia...
  34. ncbi request reprint Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Am J Psychiatry 161:985-95. 2004
    ..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis...
  35. ncbi request reprint The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 68:283-97. 2004
    ..76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement...
  36. ncbi request reprint Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness
    Philip D Harvey
    Mt Sinai School of Medicine, 1425 Madison Avenue, New York, N Y 10029, USA
    J Clin Psychiatry 65:361-72. 2004
    ..Thus, a much wider range of improvements, not widely produced by previous treatments, is required to take treatment for schizophrenia to a new level of effectiveness...
  37. ncbi request reprint Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications
    Richard S E Keefe
    Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Psychopharmacology (Berl) 169:383-9. 2003
    ....
  38. ncbi request reprint Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources
    Richard S E Keefe
    Department of Psychiatry and Behavioural Science, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 57:51-67. 2002
    ..This deficit, termed autonoetic agnosia, may result in the conclusion that self-generated thoughts come from an external source...
  39. ncbi request reprint Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial
    Del D Miller
    University of Iowa Carver College of Medicine, Psychiatry Research, 2 105 MEB, 500 Newton Rd, Iowa City, IA 52242 1000, USA
    Schizophr Res 80:33-43. 2005
    ..To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment...
  40. ncbi request reprint Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  41. ncbi request reprint Insight in first-episode psychosis
    Joseph P McEvoy
    John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
    Psychol Med 36:1385-93. 2006
    ....
  42. ncbi request reprint Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 31:2033-46. 2006
    ..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity...
  43. ncbi request reprint Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring
    Todd S Woodward
    Department of Research, Riverview Hospital, Coquitlam, Canada
    Schizophr Res 85:106-12. 2006
    ..Statistical and cognitive interpretations of the findings are discussed...
  44. ncbi request reprint Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  45. ncbi request reprint Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
    ....
  46. ncbi request reprint The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 163:426-32. 2006
    ..This study describes the reliability and validity of a new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants...
  47. ncbi request reprint The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Exp Neuropsychol 28:260-9. 2006
    ..They also suggest that the measures being considered as potential co-primary indicators of cognitive function for registration trials are significantly correlated with cognition as assessed by brief cognitive assessments...
  48. ncbi request reprint Measuring outcome priorities and preferences in people with schizophrenia
    Robert Rosenheck
    Northeast Program Evaluation Center 182, VA Connecticut Health Care System, 950 Campbell Avenue, West Haven, CT 06516, USA
    Br J Psychiatry 187:529-36. 2005
    ..Measures have not taken account of the relative importance patients place on various outcomes...
  49. ncbi request reprint One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Schizophr Res 81:1-15. 2006
    ..Haloperidol-treated patients improved only on domains of learning/memory. However, patients able to remain in treatment for the entire 52 weeks benefited more from olanzapine or risperidone treatment than haloperidol treatment...
  50. ncbi request reprint NCAM1 and neurocognition in schizophrenia
    Patrick F Sullivan
    Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599 7264, USA
    Biol Psychiatry 61:902-10. 2007
    ..Neural cell adhesion molecule 1 (NCAM1, aliases NCAM and CD56) may be a candidate gene for schizophrenia or for neurocognition in schizophrenia as supported by linkage and functional findings...
  51. ncbi request reprint The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  52. ncbi request reprint Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial
    Miranda H Chakos
    Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn, 11572, USA
    Psychiatr Serv 57:1094-101. 2006
    ..This study examined the prevalence and correlates of concomitant psychotropic medications and use of anticholinergic drugs to treat schizophrenia...